Literature DB >> 22027655

Current challenges in the clinical management of hypertension.

Luis M Ruilope1.   

Abstract

Elevated blood pressure (BP) is probably the most-important modifiable risk factor for cardiovascular disease (CVD). BP influences the development of CVD, even if levels of BP are well below the usual cut-off point that defines the presence of arterial hypertension. Adequate measurement of BP is the most-important requirement for the diagnosis and treatment of patients with suspected hypertension. The use of methodologies such as ambulatory and home BP monitoring have become powerful tools for defining the 'real' BP of patients, discarding the white-coat effect, and discovering masked hypertension. Early intervention with life-style changes and antihypertensive drugs is required to obtain the best outcome for the patient. In this sense, early use of combination antihypertensive drug therapy is recommended. The treatment of resistant hypertension-the type of elevated BP that is most difficult to control-has clearly improved over the past decade. Further studies are required to define how antihypertensive therapy should be used in the earliest stages of hypertension and for the treatment of patients with a mild-to-moderate increase in global cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22027655     DOI: 10.1038/nrcardio.2011.157

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


  82 in total

1.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

2.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

3.  Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.

Authors:  Paolo Verdecchia; Peter Sleight; Giuseppe Mancia; Robert Fagard; Bruno Trimarco; Roland E Schmieder; Jae-Hyung Kim; Garry Jennings; Petr Jansky; Jyh-Hong Chen; Lisheng Liu; Peggy Gao; Jeffrey Probstfield; Koon Teo; Salim Yusuf
Journal:  Circulation       Date:  2009-09-21       Impact factor: 29.690

4.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

5.  Feasibility of treating prehypertension with an angiotensin-receptor blocker.

Authors:  Stevo Julius; Shawna D Nesbitt; Brent M Egan; Michael A Weber; Eric L Michelson; Niko Kaciroti; Henry R Black; Richard H Grimm; Franz H Messerli; Suzanne Oparil; M Anthony Schork
Journal:  N Engl J Med       Date:  2006-03-14       Impact factor: 91.245

6.  Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension.

Authors:  Kerstin Wustmann; Jan P Kucera; Ingrid Scheffers; Markus Mohaupt; Abraham A Kroon; Peter W de Leeuw; Jürg Schmidli; Yves Allemann; Etienne Delacrétaz
Journal:  Hypertension       Date:  2009-07-20       Impact factor: 10.190

7.  Lowering blood pressure reduces renal events in type 2 diabetes.

Authors:  Bastiaan E de Galan; Vlado Perkovic; Toshiharu Ninomiya; Avinesh Pillai; Anushka Patel; Alan Cass; Bruce Neal; Neil Poulter; Stephen Harrap; Carl-Erik Mogensen; Mark Cooper; Michel Marre; Bryan Williams; Pavel Hamet; Giuseppe Mancia; Mark Woodward; Paul Glasziou; Diederick E Grobbee; Stephen MacMahon; John Chalmers
Journal:  J Am Soc Nephrol       Date:  2009-02-18       Impact factor: 10.121

8.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

9.  The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.

Authors:  Stephan Lüders; Joachim Schrader; Jürgen Berger; Thomas Unger; Walter Zidek; Michael Böhm; Martin Middeke; Wolfgang Motz; Cornelia Lübcke; Andrea Gansz; Ludmer Brokamp; Roland E Schmieder; Peter Trenkwalder; Herrmann Haller; Peter Dominiak
Journal:  J Hypertens       Date:  2008-07       Impact factor: 4.844

10.  The clock is ticking: the case for achieving more rapid control of hypertension.

Authors:  Dan R Berlowitz; Stanley Franklin
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-05       Impact factor: 3.738

View more
  13 in total

Review 1.  Azilsartan medoxomil: a review of its use in hypertension.

Authors:  Caroline M Perry
Journal:  Clin Drug Investig       Date:  2012-09-01       Impact factor: 2.859

2.  Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis.

Authors:  Ettore Malacco; Stefano Omboni; Jean-Michel Mallion; Massimo Volpe
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-02-19

3.  Sacubitril/valsartan in the treatment of arterial hypertension: an unaccomplished promise?

Authors:  Gema Ruiz-Hurtado; Luis M Ruilope
Journal:  Hypertens Res       Date:  2017-03-09       Impact factor: 3.872

4.  Renin-angiotensin system blockade: time for a reappraisal?

Authors:  Luis M Ruilope
Journal:  Eur Heart J       Date:  2014-04-09       Impact factor: 29.983

Review 5.  Olmesartan vs. ramipril in elderly hypertensive patients: review of data from two published randomized, double-blind studies.

Authors:  Stefano Omboni; Ettore Malacco; Jean-Michel Mallion; Paolo Fabrizzi; Massimo Volpe
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-01-17

Review 6.  How can resistant hypertension be identified and prevented?

Authors:  Anna Solini; Luis M Ruilope
Journal:  Nat Rev Cardiol       Date:  2013-03-05       Impact factor: 32.419

7.  Physician underutilization of effective medications for resistant hypertension at office visits in the United States: NAMCS 2006-2010.

Authors:  Valy Fontil; Mark J Pletcher; Raman Khanna; David Guzman; Ronald Victor; Kirsten Bibbins-Domingo
Journal:  J Gen Intern Med       Date:  2013-11-19       Impact factor: 5.128

8.  The use of antihypertensive fixed combinations in clinical practice needs a reappraisal.

Authors:  Luis M Ruilope; Jose R Banegas
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-02-19       Impact factor: 3.738

9.  New Strategy to Control Blood Pressure: Interactive Mobile Phone Support.

Authors:  Gema Ruiz-Hurtado; Luis M Ruilope
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-10-14       Impact factor: 3.738

10.  Estimate of nocturnal blood pressure and detection of non-dippers based on clinical or ambulatory monitoring in the inpatient setting.

Authors:  Tan Xu; Yongqing Zhang; Xuerui Tan
Journal:  BMC Cardiovasc Disord       Date:  2013-05-21       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.